Recent study of an investigational cholesterol medication called ETC-1002Monday, January 26, 2015

One of the most rewarding aspects of being involved in Clinical Research is receiving positive results for a study you’ve been involved with.

Sterling Research recently conducted a study of an investigational cholesterol medication called ETC-1002, for which positive results were recently announced. Participants who took ETC-1002 achieved an LDL-cholesterol lowering of 27% to 30%. People who took this study medication in addition to the approved cholesterol-lowering medication, Ezetemibe, experienced LDL lowering of 48%.

This medication may eventually be available for patients who may not be able to take currently available cholesterol –lowering medications, such as statins. It is the volunteers who participated in this study that make this possible; they are truly “medical heroes”.

Sterling Research is now conducting another study with this medication, to determine if it may also have a beneficial effect on Blood Pressure. To find out more about this study, call Sterling Research at 513-621-5112.